Diabetic Retinopathy/Diabetic Macular Edema

July 28, 2016

Diabetic retinopathy is a leading cause of blindness in young patients under the age of 60. Treating this disease can be challenging. The goal of new therapies is the preservation of vision with improved treatment options.

Current clinical trials for Diabetic Retinopathy and Diabetic Macular Edema (DME):

Allegro 202 B PVD:

A Phase 2, Randomized, Double-masked, Placebo-controlled Multi-center Clinical Trial designed to evaluate the safety and efficacy of Luminate® in inducing PVD in subjects with Non-Proliferative Diabetic Retinopathy.

Genentech Boulevard BP3009:

A Phase 2, Multiple-centert, multiple-dose, randomized, active comparator-controlled, double masked, parallel group, 28 week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of Ro6867461 administered intravitreally in patients with diabetic macular edema.

Allergan Palm 150998-004:

Evaluation of Abicipar Pegol (AGN-150998) in patients with decreased vision due to Diabetic Macular Edema.     *enrollment is closed

Allegro 202 B DME:

A Phase 2, randomized, controlled, double-masked trial to evaluate the safety and exploratory efficacy of Luminate® (ALG-1001) as compared to Avastin® and Focal Laser in treatment of DME.                                                          *enrollment is closed

Past clinical trials for Diabetic Retinopathy and Diabetic Macular Edema (DME):

Allergan 206207-012

A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700 microgram Dexamethasone posterior segment drug Delivery system applicator system in combination with laser photocoagulation compared to laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema.

Allergan Posurdex 206207-018

Study to assess the safety and efficacy of 700 microgram Dexamethasone posterior segment drug delivery system applicator system in the treatment of vitrectomized subjects with diabetic macular edema.